Immunological alterations and neuropsychiatry symptoms: antimicroglia antibodies and psychopathological subgroups in Alzheimer’s Disease

  • M. R. Lemke
  • M. Glatzel
  • A. E. Henneberg
Conference paper
Part of the Key Topics in Brain Research book series (KEYTOPICS)


Various immune mechanisms seem to accompany the degenerative process in Alzheimer’s disease (AD) and may contribute to the destruction of brain tissue. Acute phase proteins are components of the amyloid of senile plaques and may influence the degradation of amyloid precursor protein into amyloid beta protein (Bauer etal., 1991). Elevation of various cytokines in sera and brain tissue of AD patients and activation of the complement cascade have been demonstrated (Bauer et al., 1992; Aisen and Davis, 1994). Several studies with anti-inflammatory drugs have been reported. However, results are preliminary and not yet conclusive.


Microglial Cell Immunological Alteration Motor Restlessness Neurotic Disorder Amoeboid Microglial Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aisen PS, Davis KL (1994) Inflammatory mechanisms in Alzheimer’s disease: implication for therapy. Am J Psychiatry 151:1105–1113PubMedGoogle Scholar
  2. American Psychiatric Association (1994) Diagnostic and statistical manual, 4th edn (DSM-IV). APA, Washington DCGoogle Scholar
  3. Bauer J, Strauss S, Schreiter-Gasser U, Ganter II, Schlegel P, Witt I, Volk B, Berger M (1991) Interleukin-6 and alpha-2-macroglobulin indicate an acute phase response in Alzheimer’s disease cortices. FEBS Lett 285: 111 – 114PubMedCrossRefGoogle Scholar
  4. Bauer J, Ganter U, Strauss S, Stadtmuller G, Frommberger U, Bauer PI, Volk B, Berger M (1992) The participation of interleukin-6 in the pathogenesis of Alzheimer’s disease. Res Immunol 143: 650 – 657PubMedCrossRefGoogle Scholar
  5. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189–198Google Scholar
  6. Förstl H, Burns A, Levy P, Cairns N (1994) Neuropathologies correlates of psychotic phenomena in confirmed Alzheimer’s disease. Br J Psychiatry 165: 53 – 59PubMedCrossRefGoogle Scholar
  7. Henneberg AE, Ruffert S, Henneberg H-J, Kornhuber HH (1993a) Antibodies to brain tissue in sera of schizophrenic patients – preliminary’findings. Eur Arch Psychiatry Clin Neurosci 242: 314 – 317CrossRefGoogle Scholar
  8. Henneberg AE, Yueksektepeli B. Bauer M (1993b) Brain antibodies in sera of patients suffering from schizophrenia or schizoaffective diseases, but not from neurotic disorders: the phenomenon is independent from medication. Immunobiol 189: 220 – 221Google Scholar
  9. Lemke MR (1995) Effect of carbamazepine on agitation in Alzheimer’s inpatients refractory to neuroleptics. J Clin Psychiatry 56: 354 – 357PubMedGoogle Scholar
  10. Lemke MR (1995) Effect of carbamazepine on agitation in Alzheimer’s inpatients refractory to neuroleptics. J Clin Psychiatry 56: 354 – 357PubMedGoogle Scholar
  11. Mayeux P, Stern Y, Spanton S (1985) Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology 35: 453 – 461PubMedGoogle Scholar
  12. McKhann G, Drachman D, Folstein M, Katzman R, Peice D, Stadlan E (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ARDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34: 939 – 944PubMedGoogle Scholar
  13. McRae A, Dahlstrom A (1992) Cerebrospinal fluid antibodies: an indicator for immune responses in Alzheimer’s disease. Res Immunol 143: 663 – 667PubMedCrossRefGoogle Scholar
  14. McRae A, Ling EA, Polinsky P, Gottfries CG, Dahlstrom A (1991) Antibodies in the cerebrospinal fluid from some Alzheimer’s disease patients recognize amoeboid microglial cells in the developing rat central nervous system. Neuroscience 41: 739 – 752PubMedCrossRefGoogle Scholar
  15. McRae-Dagueurce A, Booj S, Haglig K, Rosengren L, Karsson JE, Karlsson I, Wallin A, Svennerholm L, Gottfries CG, Dahlström A (1987) Antibodies in the cerebrospinal fluid of some Alzheimer’s disease patients recognize cholinergic neurons in the rat central nervous system. Proc Acad Sci (Wash) 84: 9214 – 9218CrossRefGoogle Scholar
  16. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10: 799 – 812Google Scholar
  17. Thompson RA (1988) Laboratory investigations in clinical immunology: methods, pitfalls and clinical indications. Clin Exp Immunol 74:494–503Google Scholar

Copyright information

© Springer-Verlag/Wien 1997

Authors and Affiliations

  • M. R. Lemke
    • 1
  • M. Glatzel
    • 2
  • A. E. Henneberg
    • 2
    • 3
  1. 1.Department of PsychiatryUniversity of KielFederal Republic of Germany
  2. 2.Department of NeurologyUniversity of UlmFederal Republic of Germany
  3. 3.Clinic for Parkinson’s DiseaseBad NauheimFederal Republic of Germany

Personalised recommendations